文献速递结核与非结核分枝杆菌

BCG疫苗接种对巴西成人医护人员结核分枝杆菌感染的影响:一项嵌套临床试验

Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial.
PubMed 文献 · Lancet Infect Dis · 2024-02-26

这项嵌套在BRACE试验中的随机对照试验纳入巴西三个研究中心的1985名成人医护人员,按1:1随机接受BCG-Denmark疫苗或安慰剂,评估12个月内QuantiFERON-TB Gold Plus(QFT Plus)转阳情况。结果显示BCG组初始QFT转阳34/996(3.4%),安慰剂组32/989(3.2%),风险比1.09(95%CI 0.67-1.77;p=0.791),无显著差异。作者认为BCG-Denmark疫苗接种未降低巴西医护人员的初始QFT Plus转阳风险。

要点

  • BCG-Denmark疫苗未降低巴西成人医护人员12个月内初始QFT Plus转阳风险(RR 1.09,95%CI 0.67-1.77;p=0.791)。
  • BCG组初始QFT转阳34/996(3.4%),安慰剂组32/989(3.2%)。
  • QFT Plus转阳率在不同研究中心间无显著差异(p=0.897)。

核心结论

  • BCG-Denmark疫苗接种未降低巴西医护人员的初始QFT Plus转阳风险,作者指出需更好地理解高风险人群的结核病预防。

研究设计与样本

  • 本研究为嵌套于BRACE试验(NCT04327206)的随机对照试验亚组研究。
  • 纳入巴西三个研究中心(马瑙斯、大坎普、里约热内卢)的成人医护人员(年龄≥18岁),无论既往是否接种过BCG。
  • 排除标准包括BCG接种禁忌、接受特定结核治疗药物超过1个月、既往对BCG有不良反应、近期接种BCG或不依从分配干预。
  • 合格参与者按1:1随机分配至BCG组(皮内注射0.1 mL BCG-Denmark[丹麦株1331;AJ Vaccines,哥本哈根])或安慰剂组(皮内注射0.9%生理盐水),采用基于网络的随机化流程,可变区组长度(2、4或6),按研究中心、年龄(<40、≥40至<60、≥60岁)和合并症(糖尿病、慢性呼吸系统疾病、心脏病、高血压)分层。
  • 使用QuantiFERON-TB Gold(QFT)Plus检测(Qiagen;德国希尔登)进行基线和12个月结核感染评估;主要疗效结局为基线阴性(<0.35 IU/mL)参与者在接种后12个月内QFT Plus转阳(≥0.35 IU/mL)。

主要发现

  • 2020年10月7日至2021年4月12日期间,2568名参与者中1985名(77.3%)符合12个月QFT Plus评估条件并纳入本亚组研究;BCG组996名(50.2%),安慰剂组989名(49.8%)。
  • 1985名参与者中女性1475名(74.3%),男性510名(25.7%),中位年龄39岁(IQR 32-47)。
  • 12个月内,1985名参与者中66名(3.3%)发生QFT Plus转阳,不同研究中心间无显著差异(p=0.897)。
  • BCG组996名中34名(3.4%)发生初始QFT转阳,安慰剂组989名中32名(3.2%)发生初始QFT转阳(风险比1.09[95%CI 0.67-1.77];p=0.791)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effectiveness of BCG vaccine for adult pulmonary tuberculosis remains uncertain. In this study, we aimed to evaluate the effect of vaccination with BCG-Denmark to prevent initial and sustained interferon-γ release assay conversion in Brazilian health-care workers. METHODS: This substudy is a nested randomised controlled trial embedded within the BRACE trial (NCT04327206). Specifically, this substudy enrolled Brazilian health-care workers (aged ≥18 years) from three sites in Brazil (Manaus, Campo Grande, and Rio de Janeiro) irrespective of previously receiving BCG vaccination. Participants were excluded if they had contraindications to BCG vaccination, more than 1 month of treatment with specific tuberculosis treatment drugs, previous adverse reactions to BCG, recent BCG vaccination, or non-compliance with assigned interventions. Those eligible were randomly assigned (1:1) to either the BCG group (0·1 mL intradermal injection of BCG-Denmark [Danish strain 1331; AJ Vaccines, Copenhagen]) or the placebo group (intradermal injection of 0·9% saline) using a web-based randomisation process in variable-length blocks (2, 4, or 6), and were stratified based on the study site, age (<40, ≥40 to <60, ≥60 years), and comorbidity presence (diabetes, chronic respiratory disease, cardiac condition, hypertension). Sealed syringes were used to prevent inadvertent disclosure of group assignments. The QuantiFERON-TB Gold (QFT) Plus test (Qiagen; Hilden, Germany) was used for baseline and 12-month tuberculosis infection assessments. The primary efficacy outcome was QFT Plus conversion (≥0·35 IU/mL) by 12 months following vaccination in participants who had a negative baseline result (<0·35 IU/mL). FINDINGS: Between Oct 7, 2020, and April 12, 2021, 1985 (77·3%) of 2568 participants were eligible for QFT Plus assessment at 12 months and were included in this substudy; 996 (50·2%) of 1985 were in the BCG group and 989 (49·8%) were in the placebo group. Overall, 1475 (74·3%) of 1985 participants were women and 510 (25·7%) were men, and the median age was 39 years (IQR 32-47). During the first 12 months, QFT Plus conversion occurred in 66 (3·3%) of 1985 participants, with no significant differences by study site (p=0·897). Specifically, 34 (3·4%) of 996 participants had initial QFT conversion in the BCG group compared with 32 (3·2%) of 989 in the placebo group (risk ratio 1·09 [95% CI 0·67-1·77]; p=0·791). INTERPRETATION: BCG-Denmark vaccination did not reduce initial QFT Plus conversion risk in Brazilian health-care workers. This finding underscores the need to better understand tuberculosis prevention in populations at high risk. FUNDING: Bill & Melinda Gates Foundation, the Minderoo Foundation, Sarah and Lachlan Murdoch, the Royal Children's Hospital Foundation, Health Services Union NSW, the Peter Sowerby Foundation, SA Health, the Insurance Advisernet Foundation, the NAB Foundation, the Calvert-Jones Foundation, the Modara Pines Charitable Foundation, the United Health Group Foundation, Epworth Healthcare, and individual donors. TRANSLATION: For the Portuguese translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dos Santos PCP, Messina NL, de Oliveira RD, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial. Lancet Infect Dis. 2024. PMID: 38423021. doi:10.1016/S1473-3099(23)00818-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。